Adaptive Biotechnologies get expanded medicare coverage of clonoSEQ for assessing measurable residual disease in mantle cell lymphoma: Seattle Saturday, November 9, 2024, 15:00 Hr ...

Good day and welcome to Adaptive Biotechnologies third quarter financial results. (Operator Instructions) As a reminder, this call may be recorded. I would like to turn the call over to Karina ...

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

According to a new market research report, 'Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis ...

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...

Minimal residual disease (MRD): remaining microscopic traces of tumor cells ... of Bone Marrow Transplant and Cellular Therapies and director of the Multiple Myeloma Programs at Fox Chase Cancer ...

"In an incurable disease such as MCL, implementing ClonoSeq MRD assessment is essential not only to identify those patients at high risk of relapse but also for advancing patient-centric treatment ...

Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...

Ichnos Glenmark Innovation's cancer drug ISB 2001 shows promising results in Phase 1 trial, to be presented at ASH.

According to the company, the oral presentation will detail results from the dose-escalation portion of the study.